Myanmar national influenza programme: influenza factsheet 2019

Myanmar Influenza Surveillance – Landscape Analysis 2019 INFLUENZA FACTSHEET 2019 MYANMAR National Influenza Programme Basic information (2019) Total population 52 351 0811 Children <5 years of age 4 484 8791 Under-5 mortality rate (per 1000 live births) 48.61 Life expectancy at birth (years) 66.82 Provinces/divisions/regions/zones 17 Districts 69 Total health expenditure (% of GDP) 4.91 Income level (World Bank) Lower middle3 1https://www.who.int/southeastasia/health-topics/immunization 2https://www.who.int/gho/publications/world_health_statistics/2020/en/ 3https://data.worldbank.org/ Influenza Like Illness (ILI) Surveillance Type of ILI surveillance Sentinel Sites involved in ILI surveillance Hospitals(outpatients) Clinical case definition used for ILI case ascertainment WHO 2014 Is laboratory confirmation sought in ILI cases? Yes, 5 cases from each site per week are tested Number of ILI surveillance sites 10 Number of states/districts covered by the surveillance system 7 states and regions % of the population covered by the surveillance system - Denominator used for ILI surveillance - Reporting frequency to the national level Weekly How are the data reported? Case-based Form of the reporting tool Electronic Severe Acute Respiratory Infection (SARI) Surveillance Type of SARI surveillance Sentinel Sites involved in SARI surveillance Hospitals (inpatients) Clinical case definition used for SARI case ascertainment WHO 2014 Is laboratory confirmation sought in SARI cases? Yes, 5 cases from each site per week are tested Number of SARI surveillance sites 8 Number of states/districts covered by the surveillance system 7 states and regions % of the population covered by the surveillance system - Denominator used for SARI surveillance - Reporting frequency to the national level Weekly How are the data reported? Case-based Form of the reporting tool Electronic Influenza Surveillance – Landscape Analysis 2019 Myanmar Intensive Care Unit (ICU) surveillance Does the country have surveillance for influenza in the ICU? No Is laboratory confirmation sought in ICU cases? Not Applicable Is case-based information collected? Not Applicable Mortality surveillance Is timely all-cause mortality data (i.e. within one month) available in the country? Yes Location of influenza sentinel surveillance sites ILI / SARI Virological surveillance Does the country have virological surveillance? Yes Type of virological surveillance Sentinel – If sentinel, number of sites involved 10 Is epidemiological case information collected? Yes – If yes, are the laboratory results linked with epidemiological data? Yes Myanmar Influenza Surveillance – Landscape Analysis 2019 Average number of virological samples processed per week 39 Are samples processed from ILI or SARI surveillance systems? Yes, both systems Does the country have virus isolation capacity? Yes Does the country have RT-PCR capacity? Yes – % laboratories that perform RT-PCR 100% – RT-PCR laboratories that report to NIC - Does the country use rapid diagnostic testing for influenza surveillance? Yes – immunochromatography Does the country have sequencing capacity? Yes Does the country test for other respiratory viruses? Yes Virological data (FluNet) 0 20 40 60 80 100 0 10 20 30 40 50 60 70 80 90 100 1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 2018 2019 % P os itiv e Nu mb er of ca se s A/H1N1pm09 A/H1N1 A/H3N2 A/H5N1 A (Unsubtyped) B Yamagata B Victoria B (Unsubtyped) % Positive Plotted in R (ggplot2). Data source: FluMART, available at http://apps.who.int/flumart/ National Influenza Centre Does the country have a National Influenza Centre (NIC) or national laboratory? Yes, NIC (established in 2008) Assays routinely performed at the NIC or national laboratory RT-PCR Does the NIC have – Virus isolation capability – Antigenic characterisation capability – Antiviral susceptibility testing capability – Sequencing capability Yes Yes No Yes Does the NIC test for other respiratory viruses? Yes –Adenovirus V, Corona viruses (CoV 229E, CoV HKU1, CoV NL63, CoV OC43), Human metapneumovirus (HMPV) Enteroviruses (EV) and rhinoviruses (RV), Human parainfluenza viruses (PIV-4), Respiratory syncytial virus (RSV) Does the country have a quality control plan? Yes Does the country follow national biosafety and biosecurity policy guidelines? Yes Does the country forward samples to a WHO Collaborating Centre (CC)? Yes – National Institute of Infectious Diseases (NIID), Tokyo-Japan – How often? Twice a year Influenza Surveillance – Landscape Analysis 2019 Myanmar For technical information, please contact: Dr Pushpa Ranjan Wijesinghe, Programme Area Manager (Infectious Hazard Management). Email: wijesinghep@who.int Reporting Frequency of national reports Monthly Are epidemiological and virological data integrated? Yes, both Reported via a website? Yes – http://www.mohs.gov.mm/ Does the country report to FluID? – Year of begining of reporting – Frequency of reporting No Not Applicable Not Applicable Does the country report to FluNet? – Year of beginning of reporting – Frequency of reporting Yes 2017 Weekly Are there fixed outbreak thresholds? No Level at which data are stored, managed and analysed Both national and Sub national Has formal training on data reporting and analysis been provided to surveillance and laboratory staff? – If yes, when? – Has a training session been planned? If yes, when? No Not Applicable Not Applicable Vaccination Does the country have a formal seasonal influenza vaccination policy? No Has seasonal influenza been introduced in the public sector? – Year introduced – Recommended risk groups – Vaccination period – Northern/Southern hemisphere vaccine ? – Vaccine type Yes 2018 Healthcare workers May-July Southern Both (trivalent influenza vaccines (TIV), Quadrivalent influenza vaccine (QIV) Is seasonal influenza offered in the private sector? – Only offered to particular risk groups? – Vaccination period – Northern/Southern hemisphere vaccine ? – Vaccine type Yes Yes May-July Both Both(TIV, QIV) Is vaccine offered to Hajj and Umrah pilgrims? No Vaccine production capacity No Pandemic preparedness Does the country have a National Influenza Pandemic Preparedness Plan? – Year developed – Year last updated Yes 2006 2017 Has the country performed simulation exercises? Yes – table top, functional Are there laboratory testing strategies in place for different phases of an influenza pandemic? Yes Are there surge capacity plans? No, but intended to develop in future Does the pandemic preparedness plan include a detailed National Pandemic Vaccine Deployment Plan? – Are there priority groups? Yes Yes – healthcare workers, elderly with underlying conditions